—A new analysis took a 2-prong approach to assessing risk factors for wet age-related macular degeneration: a systematic review of the literature, coupled with a study of decades’ worth of data from ...

—Using multimodal imaging, this 10-year prospective cohort study identified markers that could help stratify patients at high risk of progressing to advanced AMD, which may help inform clinical ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...

311 subjects have been enrolled in the SOL-R study for AXPAXLI, demonstrating strong recruitment progress and enthusiasm within the retina community. The SOL-1 trial has completed randomization ahead ...

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...